Therapeutics Acquisition Corp. (RACA): Price and Financial Metrics
GET POWR RATINGS... FREE!
RACA Stock Price Chart Interactive Chart >
RACA Price/Volume Stats
|Current price||$9.99||52-week high||$21.44|
|Prev. close||$10.15||52-week low||$9.81|
|Day high||$10.15||Avg. volume||98,206|
|50-day MA||$10.16||Dividend yield||N/A|
|200-day MA||$12.75||Market Cap||140.27M|
Therapeutics Acquisition Corp. (RACA) Company Bio
Therapeutics Acquisition Corp. focuses on merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. It intends to identify and acquire a business focusing on the healthcare industry. The company was founded in 2020 and is based in Boston, Massachusetts.
RACA Latest News Stream
|Loading, please wait...|
RACA Latest Social Stream
View Full RACA Social Stream
Latest RACA News From Around the Web
Below are the latest news stories about Therapeutics Acquisition Corp that investors may wish to consider to help them evaluate RACA as an investment opportunity.
Research Alliance Corp. I Announces Effectiveness of Registration Statement for Proposed Business Combination with POINT
Therapeutics Acquisition Corp, d/b/a Research Alliance Corp. I, a Delaware corporation ("the Company") (Nasdaq: RACA) announced today that its registration statement on Form S-4 (File Number 333-254600) (as amended, the "Registration Statement"), relating to the previously announced business combination (the "Business Combination") with POINT Biopharma Inc. ("POINT"), has been declared effective by the U.S. Securities and Exchange Commission ("SEC") and that it will commence mailing a definitive
POINT Biopharma Inc. (POINT), a global radiopharmaceutical company dedicated to successfully delivering precision radioligand therapy to cancer patients, today announced that it has successfully dosed multiple patients in its Phase 3 SPLASH study evaluating the efficacy of PNT2002, the Company’s investigational 177Lu-PSMA targeted radioligand therapy for patients with PSMA expressing metastatic castration resistant prostate cancer (mCRPC) who are not eligible for chemotherapy.
POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, announced today that the U.S. Nuclear Regulatory Commission (NRC) has issued a Materials License for its new production facility located in Indianapolis, Indiana.
Life sciences industry veteran brings more than 25 years of financial and operational experienceBOSTON, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Cerevance, a private drug discovery and development company focused on brain diseases, today announced the appointment of David Lubner, a senior finance executive with more than 25 years of experience in the life sciences industry, to Cerevance’s Board of Directors. Mr. Lubner most recently served as executive vice president and chief financial officer of Ra Pharma, which was acquired by UCB in April of this year. Before joining Ra Pharma, he served as a member of the senior management team of Tetraphase Pharmaceuticals, Inc. and PharMetrics Inc., a leading patient-based pharmacy and medical claims data informatics company, and at ProScript, where Ve...
RACA Price Returns